Upadacitinib treatment in patients with moderate to severe atopic dermatitis: A retrospective single-centre Australian review of 14 patients post phase 3 clinical trial

被引：2
|
作者：
Bennett, Michaela [1 ,3 ]
Sinclair, Rodney D. [1 ,2 ]
Eisman, Samantha [1 ]
机构：
[1] Sinclair Dermatol, Melbourne, Vic, Australia
[2] Univ Melbourne, Melbourne, Vic, Australia
[3] Level 3,2 Wellington Parade, East Melbourne 3002, Australia
来源：
AUSTRALASIAN JOURNAL OF DERMATOLOGY | 2023年 / 64卷 / 01期
关键词：
atopic dermatitis; JAK; 1; inhibitors; JAK inhibitor treatment; Upadacitinib;
D O I：
10.1111/ajd.13969
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
Recent phase 2b and phase 3 clinical trials support the safety and efficacy of the selective Janus kinase (JAK)-1 inhibitor upadacitinib (UPA) in the treatment of moderate to severe atopic dermatitis (AD). However, to date, there is little experience with UPA therapy for AD in Australia. We report findings from a retrospective study to better understand the therapeutic response and side effects noted in a single-centre Australian cohort.
引用
收藏
页码：146 / 150
页数：5
相关论文
共 50 条
  • [41] Worsening of itch before flaring in patients with moderate-to-severe atopic dermatitis treated with abrocitinib: a post hoc analysis of the phase 3 JADE REGIMEN trial
    Silverberg, Jonathan, I
    Kim, Brian S.
    de Bruin-Weller, Marjolein
    Weidinger, Stephan
    Steinhoff, Martin
    Biswas, Pinaki
    Kerkmann, Urs
    Feeney, Claire
    Koppensteiner, Herwig
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 190 : II31 - II32
  • [42] Durability of Response to Abrocitinib in Patients with Moderate-to-Severe Atopic Dermatitis After Treatment Discontinuation in a Phase 2b Trial
    Melinda J. Gooderham
    Giampiero Girolomoni
    Julian O. Moore
    Jonathan I. Silverberg
    Robert Bissonnette
    Seth Forman
    Elena Peeva
    Pinaki Biswas
    Hernan Valdez
    Gary Chan
    Dermatology and Therapy, 2022, 12 : 2077 - 2085
  • [43] Durability of Response to Abrocitinib in Patients with Moderate-to-Severe Atopic Dermatitis After Treatment Discontinuation in a Phase 2b Trial
    Gooderham, Melinda J.
    Girolomoni, Giampiero
    Moore, Julian O.
    Silverberg, Jonathan, I
    Bissonnette, Robert
    Forman, Seth
    Peeva, Elena
    Biswas, Pinaki
    Valdez, Hernan
    Chan, Gary
    DERMATOLOGY AND THERAPY, 2022, 12 (09) : 2077 - 2085
  • [44] Integrated safety analysis of abrocitinib for the treatment of moderate-to-severe atopic dermatitis (AD) from the phase 2 and phase 3 clinical trial program
    Simpson, Eric L.
    Silverberg, Jonathan I.
    Nosbaum, Audrey
    Winthrop, Kevin
    Guttman-Yassky, Emma
    Hoffmeister, Karin M.
    Zhang, Min
    Farooqui, Saleem A.
    Johnson, Susan
    Thorpe, Andrew
    Rojo, Ricardo
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB150 - AB150
  • [45] Successful Achievement of Demanding Outcomes in Upadacitinib-Treated Atopic Dermatitis Patients: A Real-World, 96-Week Single-Centre Study
    Gregoriou, Stamatios
    Koumprentziotis, Ioannis-Alexios
    Kleidona, Ileana Afroditi
    Bakakis, Michail
    Hatzidimitriou, Eleni
    Douvali, Theodora
    Tsiogka, Aikaterini
    Mastraftsi, Styliani
    Vaiopoulos, Aristeidis
    Stratigos, Alexander
    DERMATOLOGY AND THERAPY, 2025, 15 (01) : 227 - 235
  • [46] Efficacy and Safety of Tralokinumab in Adolescents With Moderate to Severe Atopic Dermatitis The Phase 3 ECZTRA 6 Randomized Clinical Trial
    Paller, Amy S.
    Flohr, Carsten
    Cork, Michael
    Bewley, Anthony
    Blauvelt, Andrew
    Hong, H. Chih-ho
    Imafuku, Shinichi
    Schuttelaar, Marie L. A.
    Simpson, Eric L.
    Soong, Weily
    Arlert, Petra
    Lophaven, Katja Wendicke
    Kurbasic, Azra
    Soldbro, Lise
    Vest, Natacha Strange
    Wollenberg, Andreas
    JAMA DERMATOLOGY, 2023, 159 (06) : 596 - 605
  • [47] Long-term secukinumab efficacy in patients with moderate to severe hidradenitis suppurativa: A retrospective single-centre case series (23 patients)
    Ramos, Francisco Javier Melgosa
    Ruiz, Ramon Garcia
    Corrales, Andrea Estebanez
    Puchades, Almudena Mateu
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2023, 37 (04) : E517 - E519
  • [48] Long-term effectiveness and safety of upadacitinib for Japanese patients with moderate-to-severe atopic dermatitis: a real-world clinical study
    Hagino, Teppei
    Saeki, Hidehisa
    Fujimoto, Eita
    Kanda, Naoko
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2024, 35 (01)
  • [49] Patient-reported symptoms and quality of life in Australian patients with moderate-to-severe atopic dermatitis following treatment with abrocitinib: A post hoc analysis of JADE clinical trials
    Tan, Fiona
    Sinclair, Rodney
    Nas, Pablo Fernandez Pe
    Murrell, Dedee
    Foley, Peter
    Freeman, Michael
    Su, John
    Eisman, Samantha
    Rubel, Diana
    Spelman, Lynda
    Surian, Christine
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2022, 63 : 28 - 28
  • [50] Abrocitinib treatment in patients with moderate to severe atopic dermatitis: Consistency of efficacy responses from randomized, controlled phase 3 and phase 2b clinical trials
    Simpson, Eric L.
    Gooderham, Melinda
    King, Brett
    Taylor, Susan C.
    Rosmarin, David
    Tatulych, Svitlana
    Nduaka, Chudy
    Williams, David
    Zhang, Weidong
    Rojo, Ricardo
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (06) : AB62 - AB62
12345